No Significant Weight Change With Adjuvant Sulfonylureas

This article originally appeared here.
Share this content:
No Significant Weight Change With Adjuvant Sulfonylureas
No Significant Weight Change With Adjuvant Sulfonylureas

WEDNESDAY, June 8, 2016 (HealthDay News) -- Sulfonylureas used as add-on therapy to metformin can maintain glycemic control in type 2 diabetes, without changing body weight, according to a study published online June 6 in Diabetes, Obesity and Metabolism.

Dennis Schrijnders, from the Diabetes Center in Zwolle, Netherlands, and colleagues conducted a prospective observational cohort study involving patients with type 2 diabetes, aged 18 years and older. Participants had received metformin as monotherapy for at least one year before receiving dual therapy by the addition of a sulfonylurea for one year or more. During five years of follow-up, the within-drug yearly change in body weight after receiving add-on therapy with individual sulfonylureas was assessed. Data were included for 2,958 patients.

The researchers observed no significant weight changes within and between any of the individual sulfonylureas after intensification of treatment (P = 0.24). No significant difference in weight was seen between the add-on therapy combinations (P = 0.26). The year before intensification, the average glycated hemoglobin was 7.2 percent, and dropped to below 7.0 percent the year after intensification.

"In patients with type 2 diabetes treated in primary care, strict glycemic control can be maintained with sulfonylureas used as add-on therapy to metformin, without the offset of relevant weight changes," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »